FDA Approves Poteligeo for Rare Types of Non-Hodgkin’s Lymphoma

The United States Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab-kpkc) for the treatment of two types of rare non-Hodgkin’s lymphomas (NHL) that initially manifest in the skin.

Mycosis Fungoides (MF) and Sezary Syndrome (SS) are rare types of NHL that typically show symptoms in the skin, and ultimately spread to different sites within the body. Poteligeo represents an agent that is the first ever to be approved for SS, and has demonstrated effectiveness when compared to standard therapies for both MF and SS.

Read the FDA press release here: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm

Leave a Reply

Your email address will not be published. Required fields are marked *